Important Safety Information for Compounded Tirzepatide

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, which is FDA-approved for treating type 2 diabetes mellitus. Tirzepatide is a GIP receptor and GLP-1 receptor agonist, leading to significantly improved glycemic control in type 2 diabetics and significant weight reduction. Functionally, it stimulates insulin release from the pancreas and leads to a reduction of hyperglycemia. In addition, Tirzepatide also increases the levels of adiponectin. Its dual agonism ability leads to a more significant reduction of hyperglycemia than GLP-1 agonist agents alone and lowers the user's appetite.

Some of the adverse reactions or side effects may include diarrhea, nausea, vomiting, abdominal pain decreased appetite, indigestion, bloating, gastroesophageal reflex disease (GERD), dizziness, or constipation. Anaphylaxis, skin rash, sinus tachycardia, and hypoglycemia have also been reported. Do not use if hypersensitive to Tirzepatide or with other inactive ingredients.

Do not use past the expiration date or BUD. There are no side effects with normal dosing. The injection must be stored in the refrigerator. Keep out of reach of children and do not flush down the drain or sink.

Reporting Side Effects

Report any negative side effects of Tirzepatide to FDA MedWatch at 1-800-FDA-1088 or visit